STOCK TITAN

Daxor Corp. - DXR STOCK NEWS

Welcome to our dedicated news page for Daxor (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Daxor's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Daxor's position in the market.

Rhea-AI Summary
Daxor Corporation receives $305K NIH grant for sepsis fluid optimizer development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Daxor Corporation's CEO to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences
-
Rhea-AI Summary
Daxor Corporation provides a corporate update on its blood volume measurement technology. They are focused on improving outcomes for patients by solving the problem of accurate blood volume measurement. They have developed a new portable analyzer that can provide results in as little as 15 minutes. They have also received additional funding from the U.S. Department of Defense and National Institutes of Health for further technology development and clinical trials. Daxor continues to expand its commercial adoption and intellectual property portfolio. They reported a 20.64% increase in revenues for their single-use test kits. They have launched a new lab service and anticipate FDA approval for their next-generation analyzer by the end of the year. Daxor has also received a new $1.1 million contract from the U.S. DoD for additional capabilities to their analyzer. They have made progress in clinical outcomes utilizing their blood volume analyzer, with promising results in heart failure patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
Rhea-AI Summary
Daxor Corporation reports an increase in net assets to $30.4 million from $29.0 million. Revenue from diagnostic test kits rose by 20.64% compared to the same period last year. The company secured a $1.1 million contract from the U.S. Department of Defense. The FDA is expected to review the company's next-generation analyzer by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
Rhea-AI Summary
Daxor Corporation announces a new research letter validating the benefits of its BVA-100 diagnostic in optimizing therapy for heart failure patients. The study found a statistically insignificant correlation between pressure-volume profiles measured by CardioMEMS monitoring and Daxor's blood volume analysis diagnostic. The CEO stated that Daxor's BVA test provides clinicians with 98% accurate volume measurement, leading to improvements in patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
acquisition
-
Rhea-AI Summary
Daxor Corporation has been awarded a $1.1 million contract by the United States Defense Health Agency to add electronic medical record integration to its blood volume analyzer. This is the fifth contract awarded to Daxor for the development of their next generation technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Daxor Corp.

Nasdaq:DXR

DXR Rankings

DXR Stock Data

41.19M
2.07M
57.07%
1.53%
0.15%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Oak Ridge

About DXR

the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.